BRAF ‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Chan-Juan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for C…. Hauptthemen laut MEDLINE: Histiocytosis, Langerhans-Cell, Proto-Oncogene Proteins B-raf, Leukocytes, Mononuclear, Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Capital's Funds for Health Improvement and Research, Beijing Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The clinical relevance of BRAF ‐V600E alleles in peripheral blood mononuclear cells (PBMCs) and the prognostic impact of the mutants in cell‐free (cf) and PBMC DNAs of Langerhans cell histiocytosis (LCH) have not been fully clarified in pediatric LCH.
Methods
We retrospectively determined the levels of BRAF ‐V600E mutation in paired plasma and PBMC samples at the time of diagnosis of LCH. Subsequently, we performed a separate or combined analysis of the clinical and prognostic impact of the mutants.
Results
We assessed B RAF‐ V600E mutation in peripheral blood from 94 patients of childhood LCH. Our data showed that cf BRAF ‐V600E was related to young age, multiple‐system (MS) disease, involvements of organs with high risk, increased risk of relapse, and worse progression‐free survival (PFS) of patients. We also observed that the presence of BRAF ‐V600E in PBMCs at baseline was significantly associated with MS LCH with risk organ involvement, younger age, and disease progression or relapse. The coexisting of plasma (+) /PBMC (+) identified 36.2% of the patients with the worst outcome, and the hazard ratio was more significant than either of the two alone or neither, indicating that combined analysis of the mutation in plasma and PBMCs was more accurate to predict relapse than evaluation of either one.
Conclusions
Concurrent assessment of BRAF ‐V600E mutation in plasma and PBMCs significantly impacted the prognosis of children with LCH. Further prospective studies with larger cohorts need to validate the results of this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Beijing Key Laboratory of Pediatric Hematology-Oncology, Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- National Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
- Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
ORCID-Profile: Chan-Juan Wang, Rui Zhang, Zhi-Gang Li
Förderung
- Capital's Funds for Health Improvement and Research
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
- Funding for Reform and Development of Beijing Municipal Health Commission
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Wang, C. J., Zhu, T., Zhao, C. Z., Cui, H., Wang, D., Zhao, Z. J., Huang, X. T., Li, H. L., Liu, F. F., Zhang, R., Li, Z. G., & Cui, L. (2024). BRAF ‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31099
Vancouver
Wang CJ, Zhu T, Zhao CZ, Cui H, Wang D, Zhao ZJ, et al. BRAF ‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31099
BibTeX
@article{Wang2024,
author = {Wang, Chan-Juan and Zhu, Ting and Zhao, Chen-Zi and Cui, Hua and Wang, Dong and Zhao, Zi-Jing and Huang, Xiao-Tong and Li, Hua-Lin and Liu, Fei-Fei and Zhang, Rui and Li, Zhi-Gang and Cui, Lei},
title = {BRAF ‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31099}
}
EUVIMED